@masonat7 My biggest problem with the report is that I’m not convinced with their only-ApoB-matter assumption in PREVAIL. Though not a cardiologist, my bet is with the baseline LDL>100, LDL risks a lot more than just ApoB.
@masonat7 Yeah, they seemed to have discounted benefits from anacetrapib on obi because of PREVAIL’s shorter period of median follow-ups (3.5yrs vs 4yrs).
@puppyeh1@CacheThatCheque Believe it or not, there’re more Saizeriya in Shanghai than in Tokyo. I’ve been having Saizeriya in Shanghai for more than two decades.